Search the Newsreel

Militia Capital Management LLC Purchases Shares of 21,000 TransMedics Group, Inc. $TMDX

Militia Capital Management LLC recently acquired 21,000 shares of TransMedics Group, Inc. worth approximately $2.09 million. The company's stock, trading under NASDAQ:TMDX, currently holds a consensus "Hold" rating from analysts with an average price target of $129.55, despite missing recent quarterly earnings estimates. Institutional …

(TMDX) Risk Channels and Responsive Allocation

This article provides an AI-driven analysis of Transmedics Group Inc. (NASDAQ: TMDX), highlighting a potential shift in near-term positive sentiment and a mid-channel oscillation pattern. It identifies an exceptional short setup with a significant risk-reward ratio and outlines three distinct trading strategies: a position …

TransMedics Group (TMDX) Stock Still Looks Reasonable On Earnings Growth

TransMedics Group, Inc. Revenue Breakdown – MIL:1TMDX

TransMedics Group, Inc. (1TMDX) generated 515.53 million EUR in revenue last year. The Liver Organ Care System segment was the top performer, contributing 392.10 million EUR, an increase from the previous year. The United States was the largest regional contributor, accounting for 497.82 million …

Price to earnings forward of TransMedics Group, Inc. – NASDAQ:TMDX

This page provides financial data for TransMedics Group, Inc. (NASDAQ: TMDX), specifically focusing on its forward price-to-earnings ratio. It highlights that the information is "Made by humans" and sources its market and reference data from ICE Data Services and FactSet, respectively. The content appears …

TMDX|Transmedics Group Inc|Price:78.040|Chg%:+1.750

This article provides a comprehensive stock analysis of Transmedics Group Inc (TMDX) by TradingKey, assigning it a positive score for fundamental health and growth potential while noting its fair valuation. It highlights the company's strengths in organ transplant technology, high institutional ownership, and a …

TransMedics to present at Canaccord Genuity Growth Conference on Aug 11, showcasing organ transplant tech. TMDX $76.26 +$1.98 +2.67%

TransMedics Group, a leader in organ transplant technology, announced it will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026. The company specializes in portable organ preservation and assessment devices that improve transplant outcomes for heart, lung, and …

TMDX Initiated Coverage by UBS -- Price Target Set at $80.00

UBS has initiated coverage on TransMedics Group (TMDX) with a Neutral rating and a price target of $80.00. While GuruFocus identifies TMDX as 56.0% undervalued with strong growth potential, the mixed signals from analysts and insider selling suggest caution for investors. The company, a …

TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference

ANDOVER, Mass., July 28, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in the Canaccord Genuity 46th …

TransMedics' Aug. 11 Boston fireside chat will be webcast

TransMedics (Nasdaq: TMDX) announced its participation in the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026. The management team will present at 2:00 p.m. ET, and a live and archived webcast of the fireside chat will be available on the …

Analysts Estimate TransMedics (TMDX) to Report a Decline in Earnings: What to Look Out for

Analysts expect TransMedics (TMDX) to report a year-over-year decline in earnings but higher revenues for the quarter ended June 2026. The company is projected to post earnings of $0.50 per share, a 45.7% decrease, on revenues of $184.17 million, up 17%. Despite a positive …

TransMedics Group (NASDAQ:TMDX) Coverage Initiated by Analysts at UBS Group

UBS Group has initiated coverage on TransMedics Group (NASDAQ:TMDX) with a "neutral" rating and an $80.00 price target, suggesting a 7.70% upside from its current price. This follows mixed analyst sentiment, with the company currently holding a consensus "Hold" rating and an average target …

TransMedics Group (NasdaqGM:TMDX) Stock Price

TransMedics Group (TMDX) stock is currently trading at US$72.26, which is 31.34% lower over the last seven days and significantly undervalued compared to analyst fair value targets ranging from US$80 to US$142. The company, which specializes in organ transplant technology and logistics, has recently …

TRANSMEDICS GROUP INC : JEFFERIES CUTS TARGET PRICE TO $125 FROM $135

Jefferies has reduced its target price for TransMedics Group Inc (TMDX.O) from $135 to $125. This information was reported by Reuters on July 24, 2026. The article advises readers that its content reflects the author's opinion and should not be used as the sole …

Transmedics Group Inc (TMDX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Transmedics Group Inc (TMDX) has an earnings forecast score of 7.85 and ranks 119 out of 200 in its industry. Analysts have set an average price target of $148.50, with most recommending a "Buy" trend. The company's expected revenue for the next quarter is …

TransMedics Group, Inc. Revenue Breakdown – NASDAQ:TMDX

Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of TransMedics Group, Inc. breached their fiduciary duties to shareholders. Long-term shareholders are encouraged to contact the firm to discuss potential corporate governance reforms, return of funds to the company, …

TMDX: Transmedics Group Inc Latest Stock Price, Analysis, News and Trading Ideas

This page provides current stock information for Transmedics Group Inc (TMDX), including its latest stock price, market capitalization, volume, and key financial metrics. It also features recent news headlines related to TransMedics, such as upcoming earnings reports and expansion activities. Additionally, the page includes …

Militia Capital Management LLC Acquires New Shares in TransMedics Group, Inc. $TMDX

Militia Capital Management LLC has acquired a new position in TransMedics Group, Inc. (NASDAQ:TMDX), purchasing 16,600 shares valued at approximately $1.65 million during the first quarter. While the company's Q1 earnings missed expectations, revenue increased by 21.2% year-over-year. Analysts currently hold a consensus "Hold" …

TransMedics Group (TMDX) Projected to Post Earnings on Thursday

TransMedics Group (NASDAQ:TMDX) is expected to announce its Q2 2026 earnings on Thursday, July 30th, with analysts projecting earnings of $0.50 per share and revenue of $183.7870 million. The company's stock has a consensus "Hold" rating and a consensus target price of $134.50 from …

TransMedics Investors Partially Advance Organ Delivery Lawsuit

A federal judge ruled that TransMedics Group Inc. must face allegations from investors who claim its CEO, Waleed Hassanein, knowingly or recklessly defrauded them through unsustainable forced-bundling practices in its organ transplant "Amazon Prime model." The court found a plausible inference of conscious intent …

TMDX5812024 Bond Profile — Key Metrics

This article provides a bond profile for TransMedics Group, Inc.'s TMDX5812024 bond. Key metrics such as the issue date, maturity date, outstanding amount, face value, and coupon rate are detailed. TransMedics Group, Inc. is described as a commercial stage medical technology company focused on …

TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Recommendation of "Hold" by Brokerages

TransMedics Group, Inc. (NASDAQ:TMDX) has received an average "Hold" rating from brokerages, with a consensus 1-year price target of $134.50. The company recently missed earnings estimates, reporting $0.30 EPS against an estimated $0.62, while revenue was in line with expectations. Shares were trading at …

TransMedics to report Q2 2026 financial results on August 4

TransMedics Group, Inc. will release its Q2 2026 financial results after market close on Tuesday, August 4, 2026. The medical technology company, which specializes in organ transplant therapy, will host a conference call at 4:30 p.m. ET to discuss its performance. Investors can access …

(TMDX) Movement as an Input in Quant Signal Sets

Transmedics Group Inc. (NASDAQ: TMDX) is exhibiting a mid-channel oscillation pattern with weak near-term and long-term sentiment, despite mid-term strength. Quantitative AI models have identified an exceptional 90.8:1 risk-reward short setup, targeting a 26.4% downside with minimal risk. Three distinct trading strategies—Position Trading, Momentum …

TransMedics will webcast its second-quarter results call Aug. 4

TransMedics (Nasdaq: TMDX) announced it will release its second-quarter 2026 financial results after market close on Tuesday, August 4, 2026. Management will host a conference call and webcast at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results with investors. Prior earnings-date …

Geneos Wealth Management Inc. Makes New Investment in TransMedics Group, Inc. $TMDX

Geneos Wealth Management Inc. has initiated a new position in TransMedics Group, Inc. (NASDAQ:TMDX) during the first quarter, acquiring 30,635 shares valued at approximately $3.05 million. This investment comes amidst mixed analyst sentiment, with the stock holding a consensus "Hold" rating despite missing Q1 …

TransMedics Group Inc (TMDX) Stock Price Quote Today & Current Price Chart | Capital.com EU

This page provides current stock information for TransMedics Group Inc (TMDX), including its stock price quote, key statistics, and a company overview. It highlights TMDX as a medical technology company focused on organ transplant therapy with its OCS products. The article also touches upon …

Regency Capital Management Inc. DE Purchases Shares of 21,846 TransMedics Group, Inc. $TMDX

Regency Capital Management Inc. DE has acquired 21,846 shares of TransMedics Group, Inc. (NASDAQ:TMDX) valued at approximately $2.17 million during the first quarter. This makes Regency Capital Management Inc. DE the owner of about 0.06% of the company's stock. Insider transactions show Director Thomas …

TransMedics Group (TMDX) 44th Annual J.P. Morgan Healthcare Conference Summary

TransMedics Group (TMDX) provided a summary of their 44th Annual J.P. Morgan Healthcare Conference, outlining significant strategic, technological, clinical, and operational advancements. Key points include plans for a new facility in Somerville, the development of their OCS multiorgan perfusion platform with Gen-3 OCS Kidney …

Previsión de TMDX: precio objetivo 2027, TV

TransMedics (TMDX) Down 4.4% Since Last Earnings Report: Can It Rebound?

TransMedics: Despite Earnings Miss, Growth Story Remains Intact (NASDAQ:TMDX)

Earnings call transcript: TransMedics Q1 2026 earnings miss sends stock tumbling

TransMedics (TMDX) Q1 Earnings and Revenues Miss Estimates

TransMedics Group Inc. (TMDX) Stock Falls on Q1 2026 Earnings